Melanoma vaccine trial prompts hopeful reaction to mRNA technology
Encouraging results for a personalized mRNA vaccine for treating melanoma drew mostly hopeful responses about the technology, alongside some COVID-related false claims.
Encouraging results for a personalized mRNA vaccine for treating melanoma drew mostly hopeful responses about the technology, alongside some COVID-related false claims.
The practical takeaway
If relevant to your organization, use this trial to help explain how mRNA research is being applied beyond infectious disease vaccines.
What's happening
A recent late-stage clinical trial found that a personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42 percent compared with standard treatment. The vaccine was tailored to each patient using genetic information from their tumors and was given alongside an immunotherapy drug.
The trial’s success made national headlines. Unlike much of the conversation around mRNA COVID-19 and flu vaccines, which often circulate unfounded safety concerns, commenters largely expressed optimism about mRNA’s potential in cancer treatment. Some asked what other mRNA cancer vaccines are in development and when the melanoma treatment might become available. Others expressed distrust in mRNA and repeated longstanding false claims that mRNA vaccines “alter” DNA and have caused mass death.
Questions people are asking
- How can mRNA vaccines help treat cancer?
- What mRNA cancer vaccines are researchers working on now?
- When will the melanoma mRNA vaccine be available?
What you can do
Public-facing messaging: Assess whether sharing the trial results is relevant to organizational goals. While state and local health departments are unlikely to highlight the clinical trial, community-based or health care-focused organizations may find value in sharing mRNA-related news that draws positive responses. If the topic connects to your work, explain how researchers are studying mRNA technology for cancer treatment and other potential applications.
FAQs and owned channels: Where relevant, ensure that existing mRNA materials highlight potential uses beyond preventing infectious diseases. Use promising cancer vaccine research to broaden the public’s understanding of mRNA technology and its potential benefits.
Learn more about the Infodemiology Initiative’s monitoring methods.